

Erasmus Smit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8754122/publications.pdf>

Version: 2024-02-01

31
papers

1,995
citations

623734

14
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

4389
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent Hepatitis E virus infection across England and Wales 2009–2017: Demography, virology and outcomes. <i>Journal of Viral Hepatitis</i> , 2021, 28, 420-430.	2.0	12
2	Genomic Evidence of In-Flight Transmission of SARS-CoV-2 Despite Predeparture Testing. <i>Emerging Infectious Diseases</i> , 2021, 27, 687-693.	4.3	58
3	SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020. <i>Pathology</i> , 2021, 53, 645-651.	0.6	8
4	Lack of N2-gene amplification on the Cepheid Xpert Xpress SARS-CoV-2 assay and potential novel causative mutations: A case series from Auckland, New Zealand. <i>IDCases</i> , 2021, 25, e01233.	0.9	11
5	Global phylogeny of <i>Treponema pallidum</i> lineages reveals recent expansion and spread of contemporary syphilis. <i>Nature Microbiology</i> , 2021, 6, 1549-1560.	13.3	51
6	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. <i>HIV Medicine</i> , 2020, 21, 309-321.	2.2	3
7	Dried blood spot and mini-tube blood sample collection kits for postal HIV testing services: a comparative review of successes in a real-world setting. <i>Sexually Transmitted Infections</i> , 2019, 95, 43-45.	1.9	19
8	Human Herpes-8 virus copy to cell ratio: A diagnostic tool in primary effusion lymphoma. <i>Journal of Clinical Virology</i> , 2019, 116, 7-10.	3.1	0
9	Toward Systematic Screening for Persistent Hepatitis E Virus Infections in Transplant Patients. <i>Transplantation</i> , 2018, 102, 1139-1147.	1.0	27
10	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. <i>Clinical Infectious Diseases</i> , 2018, 69, 1136-1143.	5.8	5
11	First reported case of integrase (R263K, G163R) and reverse transcriptase (M184V)-transmitted drug resistance from a drug-naïve patient failing Triumeq. <i>Aids</i> , 2018, 32, 1905-1907.	2.2	8
12	An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2075-2082.	3.0	10
13	Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013–2015. <i>International Journal of Infectious Diseases</i> , 2016, 47, 10-14.	3.3	38
14	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
15	The management of isolated positive syphilis enzyme immunoassay results in HIV-negative patients attending a sexual health clinic. <i>International Journal of STD and AIDS</i> , 2016, 27, 798-800.	1.1	3
16	Virological failure and development of new resistance mutations according to <sc>CD</sc>4 count at combination antiretroviral therapy initiation. <i>HIV Medicine</i> , 2016, 17, 368-372.	2.2	7
17	Real-time, portable genome sequencing for Ebola surveillance. <i>Nature</i> , 2016, 530, 228-232.	27.8	1,179
18	Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3080-3086.	3.0	68

#	ARTICLE	IF	CITATIONS
19	Antiviral resistance testing. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 566-572.	3.1	10
20	Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 675-680.	3.0	8
21	HIV-1 superinfection. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 42-50.	3.1	28
22	Second line protease inhibitor (PI/r) based antiretroviral therapy (ART) after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure: impact of nucleoside (NRTI) backbone. <i>Antiviral Therapy</i> , 2012, 18, 213-219.	1.0	14
23	An Audit of access to hepatitis C services amongst Asian patients in Birmingham. <i>Journal of Infection</i> , 2011, 63, e106-e107.	3.3	0
24	Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. <i>Antiviral Research</i> , 2010, 86, 224-226.	4.1	43
25	Dynamics of Raltegravir Resistance Profile in an HIV Type 2-Infected Patient. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 843-847.	1.1	15
26	Using HIV resistance tests in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 218-222.	3.0	10
27	Raltegravir treatment response in an HIV-2 infected patient: a case report. <i>Aids</i> , 2008, 22, 1091-1092.	2.2	49
28	Stopping antiretroviral therapy. <i>Aids</i> , 2007, 21, 1673-1682.	2.2	63
29	A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2. <i>Aids</i> , 2006, 20, 1564-1565.	2.2	1
30	Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 498-502.	3.0	29
31	Resistance tests: what do clinical trials tell us?. <i>Journal of HIV Therapy</i> , 2002, 7, 80-6.	0.6	1